Micreos Funding: How Much Did They Raise & Key Investors

How Much Did Micreos Raise?
Funding & Key Investors

Micreos, a Zug-based biotechnology innovator, has successfully secured a total of $108.6M in capital to advance its proprietary endolysin-based therapeutic pipeline. This latest infusion of $24.4M represents a major strategic investment, underscoring investor confidence in the company's unique approach to addressing chronic dermatological conditions. By leveraging advanced protein engineering, Micreos continues to solidify its position as a leader in precision medicine, specifically targeting the underlying pathogens that drive skin inflammation and disease progression.

The company's growth trajectory, marked by consistent financing rounds since 2016, reflects a disciplined approach to research and development. This recent capital injection provides the necessary runway to accelerate the transition from laboratory discovery to clinical application, positioning the firm to address significant unmet medical needs in the global dermatology market.

What is Micreos?

Micreos

Business Services

Research & Development

Micreos operates at the intersection of synthetic biology and clinical dermatology. The company specializes in the discovery and development of recombinant proteins, specifically engineered endolysins designed to selectively eliminate harmful bacteria such as Staphylococcus aureus. Unlike traditional broad-spectrum antibiotics, this technology preserves the integrity of the skin's natural microbiome, offering a targeted solution for conditions like Atopic Dermatitis. By focusing on the molecular mechanisms of skin health, Micreos is redefining the standard of care for patients suffering from chronic inflammatory skin disorders.

How much funding has Micreos raised?

Micreos has raised a total of $108.6M across 4 funding rounds:

2016

Private Equity

$13.4M

2019

Unspecified

$33.8M

2021

Unspecified

$37.1M

2022

Other Financing Round

$24.4M

Private Equity (2016): $13.4M, investors not publicly disclosed

Unspecified (2019): $33.8M led by Undisclosed

Unspecified (2021): $37.1M, investors not publicly disclosed

Other Financing Round (2022): $24.4M, investors not publicly disclosed

Key Investors in Micreos

Undisclosed Investors

What's next for Micreos?

With the recent capital secured, Micreos is strategically prioritizing the advancement of its lead molecule, MEndoB, toward clinical trials scheduled for late 2026. The firm is actively seeking collaborative partnerships with industry leaders who align with its vision of revolutionizing dermatological treatments. Future milestones will focus on regulatory engagement, manufacturing scale-up, and the validation of their endolysin platform in human subjects. As the company moves closer to clinical entry, the focus will shift toward demonstrating both the safety and efficacy of their precision-targeted therapies in large-scale patient populations.

See full Micreos company page

See More Financial Insights